Regulatory Aspects of Bioactive‐Based Nanocarriers
Bibliographic record
Abstract
Nanotechnology has revolutionized drug delivery and biomolecular targeting, offering heightened efficacy and reduced off-target toxicity, particularly in cancer treatment. The emergence of nanopharmaceuticals presents a promising avenue for enhancing existing drugs’ safety and efficacy while expediting the drug discovery process. However, the evaluation of nanopharmaceuticals poses unique challenges due to their distinct physical, chemical, and biological properties. This chapter outlines guidelines for the evaluation of nanopharmaceuticals, emphasizing the need for standardized assessments of quality, safety, and efficacy to facilitate regulatory approval and industry innovation. The global regulatory landscape for nanopharmaceuticals varies widely, with different regions adopting diverse approaches. The European Union, United States, United Kingdom, Canada, Australia, China, and India each exhibit distinct regulatory frameworks and initiatives for overseeing nanotechnology applications in pharmaceuticals. Despite notable progress, gaps in regulation persist, hindering the translation of nanomedicine research into marketable products. Addressing these regulatory challenges requires international collaboration and coherence among regulatory agencies to ensure the safe and effective development of nanopharmaceuticals. Without clear guidance and leadership, the full potential of nanotechnology in medicine may remain unrealized, jeopardizing substantial investments and impeding progress in healthcare innovation.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".